Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpCAM CAR-T is a chimeric antigen receptor T (CAR-T) cell therapy designed to target EpCAM (Epithelial Cell Adhesion Molecule) expressed on cancer cells. It is being investigated for the treatment of gastrointestinal cancers, including gastric cancer and colorectal cancer. The therapy involves modifying a patient's T cells to express a CAR that recognizes EpCAM, thereby directing the T cells to specifically attack EpCAM-positive tumor cells. Clinical trials have shown a favorable safety profile and promising efficacy, particularly in gastric cancer, with observed activation of immune pathways and NKT cells contributing to the therapeutic response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EpCAM CAR-T.